Abstract | UNLABELLED: METHODS: We investigated the radiotherapeutic effect of different activities (111 and 370 MBq) of [(90)Y-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid ( DOTA)(0), Tyr(3)]octreotide in Lewis rats bearing somatostatin receptor-positive rat pancreatic CA20948 tumors of different size (0.08-15 cm(2)) in their flank. RESULTS: Dose-dependent radiotherapeutic effects of (90)Y-labeled octreotide in this rat tumor model were found. Tumor control (100% complete response) was found in animals bearing tumors of 3-9 cm(2) (mean, 7.8 cm(2)) after intravenous injection of the highest activity (370 MBq [(90) Y-DOTA(0), Tyr(3)]octreotide). In rats bearing tumors of < or =1 cm(2) or > or =14 cm(2), the effects were less pronounced (50% and 0% complete response, respectively). In tumors of < or =1 cm(2) the (90)Y radiation energy will not be absorbed completely in the tumor, whereas in tumors of > or =14 cm(2) the increased number of clonogenic and probably hypoxic tumor cells may explain the failure to reach a cure. CONCLUSION:
|
Authors | M de Jong, W A Breeman, B F Bernard, W H Bakker, T J Visser, P P Kooij, A van Gameren, E P Krenning |
Journal | Journal of nuclear medicine : official publication, Society of Nuclear Medicine
(J Nucl Med)
Vol. 42
Issue 12
Pg. 1841-6
(Dec 2001)
ISSN: 0161-5505 [Print] United States |
PMID | 11752083
(Publication Type: Journal Article)
|
Chemical References |
- Radiopharmaceuticals
- Receptors, Somatostatin
- Yttrium Radioisotopes
- octreotide, DOTA-Tyr(3)-
- Octreotide
|
Topics |
- Animals
- Dose-Response Relationship, Radiation
- Male
- Neoplasm Transplantation
- Octreotide
(analogs & derivatives, therapeutic use)
- Pancreatic Neoplasms
(mortality, radiotherapy)
- Radiopharmaceuticals
(therapeutic use)
- Rats
- Rats, Inbred Lew
- Receptors, Somatostatin
(radiation effects)
- Yttrium Radioisotopes
(therapeutic use)
|